Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
A new interactive tool that takes into account a medication's side effects and the amount of life gained can help physicians calculate what the actual price of more than 50 cancer drugs "should" be, the Wall Street Journal reports.
Developed at Memorial Sloan Kettering Cancer Center in New York, the DrugAbacus tool allows users to assign a monetary value to an additional year of life conferred by a medication, impose a "toxicity discount" based on adverse effects, and adjust for the cost of drug development. In many cases, the resulting "price" is lower than market value. For example, Blincyto (blinatumomab), used to treat a rare form of leukemia, currently costs over $64,000 for a month's treatment. But when DrugAbacus values an extra year of life at $120,000 and then deducts 15% because of side effects, the suggested price is just $12,600.
The physician who led the project told the Journal, "Right now, manufacturers have total price control, and total control of prices has led to irrational pricing behaviors."
Comment
LINK(S):
Wall Street Journal story (Subscription required)
DrugAbacus site (Free)
Background: Physician's First Watch coverage of Blincyto approval (Free)